Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nyxol in Dim Light Vision Disturbances
NCT04638660Phase 3Completed
- Sponsor
- Opus Genetics
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nyctalopia comparing Phentolamine Ophthalmic Solution 0.75% with Phentolamine Ophthalmic Solution Vehicle (2 arms). Primary endpoint: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye at 8 days. Started Dec 2020; status: completed.
02
Drugs
phentolamine
03
Conditions
nyctalopia
Beyond the preview
Go deeper on NCT04638660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638660.